BioPhy

🌎 Incredible news: BioPhy has been named to Fast Company's World Changing Ideas List! We're honored to be recognized among organizations making a difference in the world. https://www.biophy.ai/wci #FCWorldChangingIdeas #AIdrugdevelopment #AIforgood

🚀 The BioPhy team is incredibly grateful to be featured by The Philadelphia Citizen as a Business for Good. Thank you, The Philadelphia Citizen and Malcolm Burnley, for this great article and allowing the team to share our mission of using advanced AI technology to improve the probability of success and accelerate therapies to patients. 📖 It's great weekend reading, as Dave Latshaw II, PhD, MBA, CEO, BioPhy, highlights his thoughts on the future of AI. Audrey Greenberg, Founder, Center for Breakthrough Medicines also makes a profound point on AI’s impacts today: “What we’re doing today is enabling companies to be prepared for this future wave [of discoveries] that’s going to come through, where they have a significantly higher volume of molecules to deal with,” says Dave Latshaw II, PhD, MBA. Each marginal improvement could make the difference between an early-stage company staying put and moving to where the money is. “Where cash is tight, you have to get it right. AI can only be our friend,” says Audrey Greenberg. 🌟 Thank you to everyone who supports our mission. Together, we are shaping the future of drug development! #BioPhy #AI #DrugdevelopmentInnovation #BusinessForGood #PhiladelphiaCitizen + Every Cure, The Wharton School, Center for Breakthrough Medicines

Please check out BiotechTV for this great interview with Dave Latshaw II, PhD, MBA where he describes how BioPhy sees AI playing out across the biopharma landscape Click the link in the comment below to learn more from Ali Gorman and Dave Latshaw II, PhD, MBA about how AI might affect organizations of different sizes in biopharma and how BioPhy is using AI today to help increase the probabilities of success and accelerating therapies to patients.

🔬 What if AI actually fulfills its promise to revolutionize pharma productivity? ⏫ Imagine doubling the size of early-stage pipelines in six to seven years. ⚖ Pharma firms would face a thrilling dilemma: scale up headcount (good luck finding all that talent) or embrace even more technology. 🏭 But the real challenge is separating AI fact from fiction. Dave Latshaw II, PhD, MBA, co-founder and CEO of BioPhy, cuts through the hype: "True progress isn’t about marketing buzzwords but tangible results." BioPhy’s AI tools, like BioLogicAI, aim to forecast clinical trial outcomes with 80% accuracy, transforming drug development processes from end to end. 💊 The question isn’t if AI will reshape pharma but whether the industry is ready to harness its full potential. To learn more, see the great article by Brian K. Buntz of Drug Discovery & Development. 🌟 #AI #PharmaInnovation #AIDrugDevelopment #AIforGood #BioPhy

Check out this podcast by the EY team on AI in Pharma. How AI is supporting pharmaceutical manufacturing and supply chain In this episode of the EY Health Sciences and Wellness Experience podcast, host Patrick T.O'Sullivan discusses how AI is currently being used to support pharmaceutical manufacturing and supply chain. Great points made by Patrick, “nowadays you have that data at your fingertips, you can use AI to trend it, to look for insights, and to take action. At your fingertips.” At BioPhy, we bring verified, unbiased, relevant, real-time, and well-cited responses to the AI drug development process. Having this critical information “at your fingertips,” is so key for regulatory, quality, and clinical operations professionals. Just like with GPS, you need to know where you are to get to where you are going most efficiently. This EY podcast is worth a listen as its coming from one of the next expert leaders in AI drug development space, Patrick T.O'Sullivan. https://lnkd.in/gybYFSDB

Congrats Daniel Sciubba, MD, MBA Daniel Sciubba, MD, MBA elected as the AO Spine SNA representative to the AO NA Board of Directors. You are getting a very thoughtful leader. https://lnkd.in/e-ztpA3b

BioPhy is pleased to announce that our CEO, Dave Latshaw II, PhD, MBA, will speak at the PDA Capital Area Chapter Q2 Quarterly Meeting next Tuesday, June 25th. The event is in-person and virtual so anyone can attend regardless of where you are in the world! Here is the link to register: https://lnkd.in/gR7ztdCy

Great job Dave Latshaw II, PhD, MBA 🚀 Anyone on the call that would like to connect, email info@biophy.ai https://www.biophy.ai/

BioPhy will be attending the BIO International Convention in San Diego from June 3-6. Please reach out through LinkedIn or through the BIO One-on-One Partnering site to book some time with Scott Kobayashi, our SVP of Sales, to learn more about BioPhy's Predictive and Generative AI solutions that can support multiple functions, including Competitive Intelligence, Search & Evaluation, Regulatory Intelligence, SOP Gap Analysis, and more. #bio2024 #biointernationalconvention #biophy #predictiveAI #generativeAI #drugdevelopment